NO20060032L - Plasmid som koder for fibroblastvekstfaktor for behandling av hyperkolesterolemi eller diabetesrelaterte angiogeniske defekter - Google Patents

Plasmid som koder for fibroblastvekstfaktor for behandling av hyperkolesterolemi eller diabetesrelaterte angiogeniske defekter

Info

Publication number
NO20060032L
NO20060032L NO20060032A NO20060032A NO20060032L NO 20060032 L NO20060032 L NO 20060032L NO 20060032 A NO20060032 A NO 20060032A NO 20060032 A NO20060032 A NO 20060032A NO 20060032 L NO20060032 L NO 20060032L
Authority
NO
Norway
Prior art keywords
growth factor
hypercholesterolemia
diabetes
fibroblast growth
treatment
Prior art date
Application number
NO20060032A
Other languages
English (en)
Norwegian (no)
Inventor
Alexis Caron
Florence Emmanuel
Anne Caron
Francoise Finiels
Sandrine Michelet
Bertrand Schwartz
Didier Rouy
Didier Branellec
Original Assignee
Centelion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centelion filed Critical Centelion
Publication of NO20060032L publication Critical patent/NO20060032L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20060032A 2003-06-05 2006-01-04 Plasmid som koder for fibroblastvekstfaktor for behandling av hyperkolesterolemi eller diabetesrelaterte angiogeniske defekter NO20060032L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47595903P 2003-06-05 2003-06-05
US56091504P 2004-04-09 2004-04-09
US56619304P 2004-04-28 2004-04-28
PCT/EP2004/006903 WO2004108167A1 (en) 2003-06-05 2004-06-04 Plasmid encoding fibroblast growth factor for the treatment of hypercholesterolemia or diabetes associated angiogenic defects

Publications (1)

Publication Number Publication Date
NO20060032L true NO20060032L (no) 2006-01-04

Family

ID=33514717

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060032A NO20060032L (no) 2003-06-05 2006-01-04 Plasmid som koder for fibroblastvekstfaktor for behandling av hyperkolesterolemi eller diabetesrelaterte angiogeniske defekter

Country Status (11)

Country Link
US (1) US20050096286A1 (ru)
EP (1) EP1677831A1 (ru)
JP (1) JP2006526592A (ru)
KR (1) KR20060052692A (ru)
AU (2) AU2004244756A1 (ru)
BR (1) BRPI0410844A (ru)
CA (1) CA2526792A1 (ru)
EA (1) EA009390B1 (ru)
NO (1) NO20060032L (ru)
NZ (1) NZ543717A (ru)
WO (1) WO2004108167A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7038026B2 (en) 2000-05-26 2006-05-02 Centelion Purification of a triple heli formation with an immobilized oligonucleotide
US7279313B2 (en) 1995-09-15 2007-10-09 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
FR2822476B1 (fr) 2001-03-23 2004-04-02 Aventis Pharma Sa Procedes de purification et de detection de sequences cibles d'adn double brin par interaction triple helice
WO2005063807A2 (en) * 2003-12-29 2005-07-14 Centelion Treatment of coronary or peripheral ischemia
US20090305977A1 (en) * 2006-02-09 2009-12-10 Sangamo Bioscience, Inc. Method for treating peripheral arterial disease with zinc finger proteins
CN102656266B (zh) * 2009-10-15 2016-08-03 霍夫曼-拉罗奇有限公司 具有改变的受体特异性的嵌合成纤维细胞生长因子
CA2796459C (en) 2010-04-16 2016-05-24 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf-1
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
CN105828833A (zh) 2013-10-21 2016-08-03 萨克生物研究学院 突变的成纤维细胞生长因子（fgf）1及使用方法
EP3368059A4 (en) 2015-10-30 2019-03-27 Salk Institute for Biological Studies TREATMENT OF STEROID-INDUCED HYPERGLYCEMIA WITH FIBROBLAST GROWTH FACTOR (FGF) -1 ANALOGUE
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
US11746352B2 (en) * 2019-12-30 2023-09-05 Eligo Bioscience Microbiome modulation of a host by delivery of DNA payloads with minimized spread

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692435A (en) * 1978-11-06 1987-09-08 Choay, S.A. Mucopolysaccharide composition having a regulatory action on coagulation, medicament containing same and process of preparation
CA1136620A (en) * 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
IL72058A (en) * 1984-06-08 1988-03-31 Ram Lavie Method for heat and mass exchange operations
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4686113A (en) * 1985-12-18 1987-08-11 Fairchild Semiconductor Corporation Plasma confinement in a low pressure electrically grounded R.F. heated reactor and deposition method
US5827826A (en) * 1986-03-03 1998-10-27 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compositions of human endothelial cell growth factor
ZA874487B (en) * 1986-06-23 1987-12-23 Merck & Co.,Inc. Novel hmg-coa reductase inhibitors
CA1322163C (en) * 1986-07-03 1993-09-14 Kenneth A. Thomas, Jr. Plasminogen activator production
US5045565A (en) * 1987-03-09 1991-09-03 The Procter & Gamble Company Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain
US4965200A (en) * 1989-06-23 1990-10-23 Merck & Co., Inc. Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs
FR2663639B1 (fr) * 1990-06-26 1994-03-18 Rhone Poulenc Sante Melanges de polysaccharides de bas poids moleculaires procede de preparation et utilisation.
WO1993008828A1 (en) * 1991-11-08 1993-05-13 Syntex-Synergen Neuroscience Joint Venture Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US6086582A (en) * 1997-03-13 2000-07-11 Altman; Peter A. Cardiac drug delivery system
AU8855798A (en) * 1997-07-03 1999-01-25 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel composition for treating, preventing and/or delaying ischemic cell death
EP1563866B1 (en) * 1998-02-05 2007-10-03 Biosense Webster, Inc. Intracardiac drug delivery
US20020122792A1 (en) * 1998-07-24 2002-09-05 Thomas J. Stegmann Induction of neoangiogenesis in ischemic myocardium
US6102887A (en) * 1998-08-11 2000-08-15 Biocardia, Inc. Catheter drug delivery system and method for use
US20010034023A1 (en) * 1999-04-26 2001-10-25 Stanton Vincent P. Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
US20020037508A1 (en) * 2000-01-19 2002-03-28 Michele Cargill Human single nucleotide polymorphisms
US6988004B2 (en) * 2000-05-16 2006-01-17 Bioheart, Inc. Method for inducing angiogenesis by electrical stimulation of muscles
KR100861240B1 (ko) * 2000-08-15 2008-10-02 카디오배스큘러 바이오 떼러퓨틱스, 인크. 생물학적으로 활성인 인간 산성 섬유아세포 성장인자의제조방법과 맥관형성 촉진을 위한 그 용도
BR0116014A (pt) * 2000-12-07 2003-10-21 Gencell Sa Polinucleotìdeo, cassete de expressão, vetor, medicamento, composição farmacêutica, uso de um polinucleotìdeo, animal transgênico, e, método de expressar um gene de interesse terapêutico in vivo

Also Published As

Publication number Publication date
CA2526792A1 (en) 2004-12-16
EP1677831A1 (en) 2006-07-12
WO2004108167A1 (en) 2004-12-16
JP2006526592A (ja) 2006-11-24
EA200501846A1 (ru) 2007-12-28
KR20060052692A (ko) 2006-05-19
AU2010257389A1 (en) 2011-01-27
EA009390B1 (ru) 2007-12-28
BRPI0410844A (pt) 2006-06-27
NZ543717A (en) 2008-06-30
US20050096286A1 (en) 2005-05-05
AU2004244756A1 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
NO20060032L (no) Plasmid som koder for fibroblastvekstfaktor for behandling av hyperkolesterolemi eller diabetesrelaterte angiogeniske defekter
Basir et al. Effect of early initiation of mechanical circulatory support on survival in cardiogenic shock
WO2002064157A3 (en) Localized myocardial injection method for treating ischemic myocardium
Cutlip et al. Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction
WO2001013031A3 (en) Dose of an angiogenic factor and method of administering to improve myocardial blood flow
NO973023L (no) Fremgangsmåte og preparater for behandling av allergisk rhinitt og andre forstyrrelser ved anvendelse av deskarboetoksyloratadin
WO2006121532A3 (en) Treatment for heart disease
PT1267897E (pt) Tratamento da insufuciencia cardiaca congestiva com sangue autologo previamente tratado
WO2002089856A8 (en) Techniques and compositions for treating cardiovascular disease by (in vivo) gene delivery
WO2002004008A3 (en) Methods of therapy with thrombin derived peptides
WO2000021548A3 (en) Angiogenically effective unit dose of fgf and method of administering
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
WO2002000210A3 (en) Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
Dai et al. Renal sympathetic denervation suppresses ventricular substrate remodelling in a canine high-rate pacing model
Liu et al. Vascular endothelial growth factor-mediated, endothelium-dependent relaxation in human internal mammary artery
Sra et al. Atrial fibrillation: epidemiology, mechanisms, and management
Abo-Salem et al. Reversal of novel oral anticoagulants
Alunni et al. The beneficial effect of extracorporeal shockwave myocardial revascularization: Two years of follow-up
Gowda et al. Treatment of refractory angina pectoris
EA200200533A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ СЕРДЕЧНО-СОСУДИСТОГО ЗАБОЛЕВАНИЯ ДОСТАВКОЙ ГЕНОВ in vivo
Garg et al. Acute myocardial infarction secondary to thromboembolism in a patient with atrial fibrillation
Nademanee et al. Long-term antithrombotic treatment for atrial fibrillation
AU655780B2 (en) A method and composition for the protection of a metabolic recovery of ischemic cardiac tissue
Herlitz et al. Delay time between onset of myocardial infarction and start of thrombolysis in relation to prognosis
WO2002058720A3 (en) Angiogenically effective unit dose of fgf-2 and method of use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application